Screener
Pacific Biosciences of California PACB United States — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The source filing: Pacific Biosciences of California’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 4:03 PM EST
- Fiscal year
- FY2025
- Accession
- 0001299130-26-000034
FAQ
- What is Pacific Biosciences of California's united states — total revenue?
- Pacific Biosciences of California (PACB) reported united states — total revenue of $17.43M in Q4 2025.
- How has Pacific Biosciences of California's united states — total revenue changed year-over-year?
- Pacific Biosciences of California's united states — total revenue decreased by 7.4% year-over-year, from $18.83M to $17.43M.
- What is the long-term trend for Pacific Biosciences of California's united states — total revenue?
- Over 3 years (2022 to 2025), Pacific Biosciences of California's united states — total revenue has grown at a 1.4% compound annual growth rate (CAGR), from $66.8M to $69.7M.
- What does united states — total revenue mean?
- This metric represents the total gross revenue generated from the sale of sequencing platforms, consumables, and related services within the United States geographic market. It serves as a key indicator of the company's commercial penetration and demand for genetic analysis solutions in its primary domestic region. Tracking this figure helps investors assess the company's ability to capture market share and scale operations within the domestic biotechnology and clinical research landscape.
Ask your AI about Pacific Biosciences of California's united states — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude